Compare CNNE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNNE | ARVN |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 609.0M | 516.2M |
| IPO Year | 2017 | 2018 |
| Metric | CNNE | ARVN |
|---|---|---|
| Price | $14.83 | $8.96 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | ★ $20.25 | $15.05 |
| AVG Volume (30 Days) | 411.3K | ★ 835.4K |
| Earning Date | 05-11-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.47% | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | 0.12 | ★ 1.70 |
| Revenue | ★ $499,700,000.00 | $262,600,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.28 |
| Revenue Growth | ★ 3.37 | N/A |
| 52 Week Low | $10.46 | $6.74 |
| 52 Week High | $19.88 | $14.22 |
| Indicator | CNNE | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 61.46 |
| Support Level | $14.05 | $7.90 |
| Resistance Level | $15.14 | $9.65 |
| Average True Range (ATR) | 0.42 | 0.39 |
| MACD | -0.03 | 0.09 |
| Stochastic Oscillator | 67.83 | 62.11 |
Cannae Holdings Inc is an investment holding company that acquires and actively manages equity interests in operating businesses across various industries. The Company focuses on long-term ownership and seeks to create value by supporting the growth and operations of its portfolio companies through management expertise and strategic oversight. The Company operates through four reportable segments: Restaurant Group, which includes the operations of O'Charleys and 99 Restaurants; Alight, which represents its ownership interest in a technology-enabled human capital and employee benefits solutions provider; Black Knight Football Club (BKFC), which holds interests in professional football clubs; and JANA, which represents its investment in an investment management firm.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.